公开(公告)号：WO2005032492A3

公开(公告)日：2007-04-12

申请号：PCT/US2004033255

申请日：2004-10-08

Applicant: MUSC FOUND FOR RES DEV ,  MEIER G PATRICK ,  BAI AIPING ,  ZHOU DAOHONG

Inventor： MEIER G PATRICK ,  BAI AIPING ,  ZHOU DAOHONG

IPC: C07F9/02 ,  A61K20060101 ,  A61K31/265 ,  C07C327/00 ,  C07F9/09

CPC classification number: C07F9/091

Abstract: Compounds that are heteroatom substituted alkyl derivatives of tricyclodecan-9-yl-xanthogenate, and pharmaceutical compositions of these compounds, are disclosed. Methods of treating a disease or disorder in a subject and methods of protecting normal tissues in a subject from toxicity associated ionizing radiation or chemotherapy using compositions comprising these novel compounds are also disclosed. The invention also concerns methods of treating a disease or disorder in a subject using compositions that include these novel compounds while concurrently or consecutively treating the subject with ionizing radiation or a chemotherapeutic agent.

Abstract translation: 公开了作为三环癸基-9-基 - 黄原酸酯的杂原子取代的烷基衍生物的化合物和这些化合物的药物组合物。 还公开了治疗受试者的疾病或病症的方法以及使用包含这些新化合物的组合物来保护受试者中与正常组织相关的电离辐射或化学疗法的组合物的方法。 本发明还涉及使用包括这些新化合物的组合物治疗受试者的疾病或病症的方法，同时或连续地用电离辐射或化学治疗剂治疗受试者。

公开(公告)号：WO2010054223A1

公开(公告)日：2010-05-14

申请号：PCT/US2009/063586

申请日：2009-11-06

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  BIELAWSKA, Alicja ,  BAI, Aiping ,  SZULC, Zdzislaw, M. ,  HANNUN, Yusef, A. ,  NORRIS, James ,  XIANG, Liu

Inventor： BIELAWSKA, Alicja ,  BAI, Aiping ,  SZULC, Zdzislaw, M. ,  HANNUN, Yusef, A. ,  NORRIS, James ,  XIANG, Liu

IPC: A01N37/18 ,  A61K31/16

CPC classification number: A61K31/16 ,  C07C233/18

Abstract: The presently disclosed subject matter provides compounds of the formula, formula (Ia): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, and n are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting acid ceramidase and ceramidase-related activity, and their use as drugs and prodrugs in the treatment and/or prevention of diseases associated with undesirable ceramidase or sphingosine kinase activity, including, but not limited to, cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, asthma, and atopic dermatitis.

Abstract translation: 目前公开的主题提供式（Ia）化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，X，Y和n如本文所定义。 还公开了制备如上所述的式的化合物，其用于抑制酸性神经酰胺酶和神经酰胺酶相关活性的方法，以及它们作为药物和前药用于治疗和/或预防与不期望的神经酰胺酶或鞘氨醇相关的疾病的用途 激酶活性，包括但不限于癌症，癌症转移，动脉粥样硬化，狭窄，炎症，哮喘和特应性皮炎。

公开(公告)号：WO2005032492A2

公开(公告)日：2005-04-14

申请号：PCT/US2004/033255

申请日：2004-10-08

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  MEIER, G., Patrick ,  BAI, Aiping ,  ZHOU, Daohong

Inventor： MEIER, G., Patrick ,  BAI, Aiping ,  ZHOU, Daohong

IPC: A61K

CPC classification number: C07F9/091

Abstract: Compounds that are heteroatom substituted alkyl derivatives of tricyclodecan-9-yl-xanthogenate, and pharmaceutical compositions of these compounds, are disclosed. Methods of treating a disease or disorder in a subject and methods of protecting normal tissues in a subject from toxicity associated ionizing radiation or chemotherapy using compositions comprising these novel compounds are also disclosed. The invention also concerns methods of treating a disease or disorder in a subject using compositions that include these novel compounds while concurrently or consecutively treating the subject with ionizing radiation or a chemotherapeutic agent.

Abstract translation: 公开了作为三环癸基-9-基 - 黄原酸酯的杂原子取代的烷基衍生物的化合物和这些化合物的药物组合物。 还公开了治疗受试者的疾病或病症的方法和使用包含这些新化合物的组合物来保护受试者中与正常组织相关的电离辐射或化学疗法的组合物的方法。 本发明还涉及使用包括这些新化合物的组合物治疗受试者的疾病或病症的方法，同时或连续地用电离辐射或化学治疗剂治疗受试者。